Last reviewed · How we verify
OXERVATE® 0.002%
OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy.
OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy. Used for Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage).
At a glance
| Generic name | OXERVATE® 0.002% |
|---|---|
| Also known as | cenegermin-bkbj |
| Sponsor | Dompé Farmaceutici S.p.A |
| Drug class | Recombinant growth factor |
| Target | Nerve growth factor receptor (TrkA, p75NTR) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Nerve growth factor is a naturally occurring protein that stimulates the growth and survival of nerve cells. In neurotrophic keratopathy, corneal nerves are damaged or absent, leading to loss of protective sensation and corneal ulceration. By supplying exogenous NGF topically, OXERVATE restores corneal innervation and promotes epithelial healing through neurotrophic signaling pathways.
Approved indications
- Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage)
Common side effects
- Eye pain
- Conjunctival hyperemia
- Punctate keratitis
- Foreign body sensation
Key clinical trials
- DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis (PHASE4)
- Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis (PHASE4)
- NGF Treatment for Patients With Neuropathic Corneal Pain (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OXERVATE® 0.002% CI brief — competitive landscape report
- OXERVATE® 0.002% updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI